The data indicate that patients with a poor outcome have enhanced IDO activity in the early stage of sepsis, leading to increased levels of KYN and KYNA, and provoking the expression of TGF-β and IL-6 and the development of endotoxin tolerance. The gene discussed is IDO1; the disease is Sepsis.